Author

Igor Mochalkin

Vividion Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Aaron Nathan SneadiD· 1 shared Antonio Esparza-OrosiD· 1 shared Benjamin D. HorningiD· 1 shared Brian N. CookiD· 1 shared Chanyu Yue· 1 shared Cynthia BerryiD· 1 shared David S. WeinsteiniD· 1 shared Eileen TraniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron Nathan SneadORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2

Joseph E. Klebba, Nilotpal Roy, Steffen M. Bernard, Stephanie Grabow, Melissa A. Hoffman, Hui Miao, Junko Tamiya, Jinwei Wang, Cynthia Berry, Antonio Esparza-Oros, Richard D. Lin, Yongsheng Liu, Marie Pariollaud, Holly Parker, Igor Mochalkin, , Matthew P. Patricelli

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

Science · Oct 9, 2025Peer-reviewedCancer Biology